Nanosynex News
6 articles
Nanosynex seeks to bring rapid COVID-19 tests to Israel
Israeli Diagnostics Firm NanoSynex Aiming for European Market Entry for AMR Test by 2023
Israeli diagnostics company NanoSynex is aiming to disrupt the market for antibiotic susceptibility testing with its rapid testing platform. The company recently received a €2.6 million ($3.1 million) grant from the European Commissions Horizon 2020 program to support the development of its prototype and entry into the European market by 2023. NanoSynex also has plans to enter the US market in 2025. The companys approach uses a phenotypic method to monitor bacterial growth and determine antibiotic effectiveness. NanoSynex believes its same-day results and advanced technology will give it an advantage over larger competitors in the market. The company is currently seeking additional funding to support its growth and product development.
InvestmentExpand
מישל היימן ודיאן אבנצור - Forbes 30 Under 30
Nanosynex, founded in 2017, aims to combat antibiotic resistance by developing a diagnostic device that identifies the most effective antibiotic for a specific bacterial infection. The device provides direct answers within a few hours, faster than existing tests. Nanosynex has partnered with French medical diagnostics company Biosynex for distribution in over sixty countries. The company has raised $1.75 million from family offices and various business investors, as well as receiving support from the Innovation Authority and a grant of $3 million from the European Horizon 20/20 program. Nanosynex hopes to make the product available in the European market by 2022. The companys team consists of employees from Brazil, France, Russia, and the United States.
InvestmentPartners
Nanosynex aims to solve antibiotic resistance
Nanosynex, a company founded in 2017, has developed a method to detect which antibiotic is most effective for a specific infection. By using this method, ineffective antibiotics can be avoided and the use of broad-spectrum antibiotics can be reduced. The company aims to provide more effective and faster treatment without encouraging antibiotic resistance. Nanosynex has acquired the development rights for a laboratory device and has partnered with French company Biosynex. It has raised $1 million from the Lamed Holdings fund, received a $2.5 million grant from the European Union Horizon 2020 program, and received $500,000 from the Israel Innovation Authority. The company plans to perform a clinical trial in 2021 and enter the European market in 2022.
CustomersPartnersInvestment
Diagnostic test from Israel aims to stop superbug surge
Israeli startup Nanosynex has developed a diagnostic test that can determine which bacteria in a patients body are resistant to antibiotics in just four hours. This allows physicians to quickly prescribe the appropriate antibiotics, potentially reducing the development of antibiotic-resistant bacteria. Nanosynex has created a kit that will be sold to laboratories, containing disposable cards, a fluorescent reading device, and software for analysis. The technology is based on microfluidic features, requiring a smaller quantity of bacteria than other testing technologies. Nanosynex was founded in 2017 and has raised $1 million in funding. The company has participated in IBMs accelerator for healthcare startups and receives blood for testing from Rambam Healthcare Campus and Shaare Zedek Medical Center in Israel.
Customers
